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Four months prior to the admission, she began 
to notice enlargement of her left eye, which became 
gradually increasing in size, accompanied with 
mild and intermittent pain. She also experienced 
diplopia and a decrease in visual acuity of her left 
eye, but there was no complain of fl oaters. The 
ophthalmologist who examined her at that time 
suspected a neurological problem of the extraocular 
muscles of her left eye, and she was subsequently 
hospitalized for further investigations.
Head magnetic resonance imaging (MRI) 
conducted at that time revealed left maxillary, 
left frontal, and left ethmoid sinusitis. Three 
weeks after the MRI, the patient underwent head 
computed tomography (CT) scan, which showed 
left retrobulbar mass infi ltrating the medial rectus 
and inferior rectus muscle of the left eye and roof 
of the left maxillary and left ethmoid sinus with 
destruction of the inferior orbital rim (fi gure 1A).
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Figure 1   Head computed tomography of the 
patient at the time of admission (A) and after the 
administration of voriconazole (B).
Systemic lupus erythematosus (SLE) is an 
autoimmune disease with a broad clinical 
manifestation characterized by production of 
antibodies against cellular nuclear components. 
The prevalence of SLE among many countries 
is variable, ranging from 2.9 to 400 per 100,000. 
In Cipto Mangunkusumo General Hospital, the 
incidence of SLE between 1990 and 1998 is 37.3 
per 10,000 hospitalization.1 
Patients with autoimmune disease have at least 
twofold risk of acquiring infections compared 
with healthy individuals. This may be due to the 
immunosuppresant therapy but could also caused 
by the primary immune dysregulation that was 
the basis for the pathogenesis of their disease, or 
other autoimmune disease manifestations such as 
lymphopenia.2 Infection is the main factor increasing 
the mortality and morbidity of SLE patients. A 
study in New York conducted between 1966 and 
1976 involving 223 SLE patients reported 150 
cases of infection, of which 23 were opportunistic 
infection: 12 were candidiasis while 11 others were 
deep fungal infection. The use of corticosteroids in 
SLE is the main factor that predispose patients to 
infection, particularly fungal infection.3 
Aspergillosis is the term used to denote all disease 
caused by any one of the pathogenic and allergenic 
species of Aspergillus. The annual incidence of 
aspergillosis in the United States is reported to 
be 1–2 per 100,000.4 Aspergillus fumigatus is 
the cause of most cases of invasive aspergillosis, 
almost all cases of chronic aspergillosis, and most 
allergic syndromes. The mortality rate of invasive 
aspergillosis is 50% when properly diagnosed and 
treated; otherwise it could be as high as 100%.5
CASE REPORT
A 21-year-old woman presented with one-week 
history of throbbing headache. The pain, which 
radiated to the upper molar, was intermittent at 
fi rst but had been gradually increasing in intensity 
and eventually became constant. The pain was 
not relieved by analgesics such as paracetamol or 
mefenamic acid.
The patient was diagnosed with SLE 4 years 
earlier and had since had regular follow-ups at the 
rheumatology clinic at our institution. She was 
treated with methylprdnisolone 16 mg t.i.d. and 
mycophenolate mofetil (MMF) 500 mg b.i.d.
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Three months prior to the admission, the patient began 
experiencing throbbing headache, which radiated to the upper 
molar and accompanied with nausea and vomiting. Since then 
she also had 15 kg decrease in body weight.
With suspicion of a tumor, the patient had a nasopharyngeal 
biopsy, which at that time only showed chronic sinusitis. 
A retrobulbar biopsy guided by nasoendoscopy conducted 
one week before the admission showed large necrotic areas 
containing Aspergillus hyphae (fi gure 2). There were also found 
fragments of granulation tissue and blood clots resembling the 
histopathological feature of aspergillosis.
Physical examination at the time of admission showed a 
blood pressure of 100/70 mmHg, pulse rate of 84 beats/min 
with good pulse volume, and respiratory rate of 16 breaths/
min. Her body weight and height was 48 kg and 158 cm, 
respectively, with BMI of 19.27 kg/m2. On eye examination 
we found proptosis, erythema, and edema of the left eye. 
There was no supra- or infraorbital tenderness.
Laboratory examination revealed anemia with hemoglobin 
of 10.3 g/dL, mean corpuscular volume of 76 fL, mean 
corpuscular hemoglobin of 25 pg, and mean corpuscular 
hemoglobin concentration of 33 g/dL; hematocrit was 32%, 
leukocyte count was 9.9 × 103/mm3 (differential count: 
basophils 0%, eosinophils 0%, stabs 2%, segmenters 85%, 
lymphocytes 13%, and monocytes 0%), platelet count was 
422 × 103/mm3. Serum ureum level was 37 mg/dL (normal 
value <50 mg/dL), serum creatinine was 0.5 mg/dL (normal 
value 0.6–1.2 mg/dL), aspartate aminotransferase (AST) was 
19 IU/L (normal value <27 IU/L), alanine aminotransferase 
(ALT) was 12 IU/L (normal value <36 IU/L), albumin was 
3.8 g/dL, random blood glucose was 99 mg/dL, sodium was 
139 mEq/L, potassium was 3.8 mEq/L, and chloride was 103 
mEq/L. Complement component (C)3 and C4 was 95.40 mg/
dL (normal value 90–180 mg/dL) and 39 mg/dL (normal value 
10–40 mg/dL), respectively. Anti–double-stranded DNA (anti-
dsDNA) was 1061 IU/mL (normal value 0–100 IU/mL). Her 
chest radiograph and electrocardiograph were unremarkable.
The patient’s diagnoses at the time of admission were 
chronic headache; retrobulbar aspergillosis; SLE with renal, 
hematological, and musculoskeletal involvement; and 
microcytic hypochromic anemia.
The patient was treated with tramadol 1 amp diluted in 
500 mL of normal saline infused intravenously over 8 hours, 
paracetamol 750 mg, ibuprofen 200 mg, amitriptyline 5 mg, 
diazepam 1 mg, diclofenac sodium 50 mg t.i.d, MMF 500 
mg b.i.d, methylprednisolone 4 mg t.i.d, calcium hydrogen 
phosphate 500 mg and cholecalciferol 133 IU t.i.d., folic acid 
1 tab t.i.d., lansoprazole 30 mg q.d., and sucralfate syrup 5 
mL t.i.d.
For the aspergillosis, she was treated with amphotericin 
B with a dose of 5 mg/day, which was gradually increased (5 
mg/day) until a dose of 0.5–1 mg/kg body weight/day. After 
14 days, the treatment was continued with oral itraconazole 
400 mg q.d.
After one month of hospitalization, the headache and 
orbital edema had improved. The patient was thus discharged 
with outpatient follow-up and instruction to continue therapy 
with itraconazole 400 mg q.d., MMF 500 mg b.i.d., and 
methylprednisolone 8 mg t.i.d. At the time of discharge, she 
was in good condition with stable hemodynamics. 
Magnetic resonance imaging at the end of the hospitalization 
showed malignant mass in the left retrobulbar area, which 
infi ltrated the medial and lateral rectus muscle, left distal optic 
nerve, and left maxillary sinus. There were also left maxillary, 
ethmoid, and sphenoid sinusitis. Intracerebral area showed no 
abnormalities.
Two weeks after being discharged, the patient was 
rehospitalized because her headache, now worse than before, 
and left eye swelling had recurred. Laboratory examination 
results at that time were as follows: hemoglobin 8.7 g/dL, 
leukocyte count 22.43 × 103/mm3, platelet count 271 × 103/
mm3, erythrocyte sedimentation rate 6 mm/hr, anti-dsDNA 
370.5 IU/mL, C3 80.04 mg/dL, C4 39.36 mg/dL, antinuclear 
antibodies was positive at 1:3200 dilution with speckled and 
centromere pattern; aspartate aminotransferase was normal 
(29 U/L), but there was an increase in ALT level (167 U/L); 
Figure 2   Aspergillus sp. hyphae in retrobulbar biopsy specimens. Original magnifi cation 200 × (left), 1000 × (right).
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serum ureum 36 mg/dL, serum creatinine 0.3 mg/dL, IgM 
anticardiolipin antibodies (ACA) 5.3, IgG ACA 6.8, IgM 
β2-glycoprotein I (β2GPI) 3.9, IgG β2GPI 1.9. Hemostasis: 
prothrombin time 13.1 sec (1 × control; normal value 9.8–
12.6 sec), activated partial thromboplastin time 36.2 sec (1 
× control; normal value 31.0–47.0 sec), and international 
normalized ratio 1.18.
Electroencephalography showed slow activity in the 
bilateral (predominantly left) frontal area. Diagnosis of the 
Department of Neurology was paraparesis ec. corticosteroid-
induced myopathy. Referral to the Department of 
Ophthalmology returned with these results: proptosis of the 
left eye; visual acuity was >3/60 (right eye) and 0.5/60 (left 
eye); the anterior segment of both eyes and fundus of the right 
eye was normal but there was optic nerve head atrophy of the 
left eye; intraocular pressure of the right and left eye was 15.5 
and 13, respectively. Head CT scan showed left retrobulbar 
mass fi lling the sphenoid, ethmoid, and left maxillary sinus, 
with infi ltration of rectus muscles of the eye, apical segment 
of the left optic nerve, and intracranially into the left parasellar 
area.
Due to the deteriorated condition of her left eye, the patient 
was planned to undergo left orbital exenteration. However, 
her family did not consent to the plan; so we decided to 
administer an alternative treatment course of intraconal 
irrigation of amphotericin B 2.5 mg (25 mL) for 10 days. 
Before the initiation of treatment, we performed biopsy to 
obtain specimen for culture and resistency test.
On day 9 of the amphotericin B treatment, the patient 
developed fever. On physical examination we found a 
temperature of 38.1°C with normal pulse rate (96 beats/min). 
Laboratory examination revealed leukocytosis (18.28 × 103/
mm3); C-reactive protein was 51.4 mg/L and procalcitonin 
was >5 μg/L. She was diagnosed with sepsis ec. left orbital 
cellulitis. Amphotericin B was substituted with itraconazole 
400 mg q.d. and meropenem 1 g t.i.d. for 14 days. Blood and pus 
cultures showed Aspergillus fumigatus, which in susceptibility 
test showed sensitivity to voriconazole and amphotericin B 
(with dose adjustment), and resistant to itraconazole. It was 
thus decided to administer intravenous voriconazole 300 mg 
b.i.d. on the fi rst day continued with a dose of 200 mg b.i.d. 
for 10 days. At day 10 her treatment was continued with oral 
voriconazole 200 mg b.i.d. for 4–6 weeks.
A                                                          B
Figure 3   Results of blood and pus cultures: (A) colonies of 
Aspergillus fumigatus; (B) susceptibility test showed resistance 





Computed tomography after the administration of 
voriconazole showed pathologically enhanced heterogeneous 
lesion with air component in the left retrobulbar (intra- and 
extraconal) area infi ltrating the rectus and oblique muscles of 
the eye and left optic nerve, with destruction of the ethmoid, 
sphenoid, inferior orbital wall and sphenoid wing, extending 
intracranially into the left parasellar area, and fi lling the left 
ethmoid, left maxillary, and sphenoid sinus (fi gure 1B). There 
was signifi cant reduction of the mass in comparison with the 
previous CT. There was also left buccal cellulitis suggestive of 
fungal infection. The Department of Radiology confi rmed the 
presence of intracranial infi ltration; however, the intracerebral 
area in cavernous sinus was still intact.
Figure 4   Condition of patient’s left eye at the time of 
rehospitalization (left) and 4 weeks later (right).
After 4 weeks of hospitalization, the symptoms of headache 
and orbital edema had improved, although the vision loss of 
her left eye was permanent. Laboratory results were normal; 
ALT had decreased to 52 U/L, and was 7 U/L in a follow-up 
examination one month later. The patient’s lupus activity was 
also under control.
DISCUSSION
Systemic lupus erythematosus is a multisystem disorder 
caused by production of immune complex-forming 
autoantibodies and complement resulting in tissue damage.6 
Infection is the main cause of morbidity and mortality in SLE 
patients, whose dysfunction of immune system is considered 
to play a role. Besides, administration of steroids and other 
immunosuppressive agents also contribute to the increased 
susceptibility to infection.3 Our patient, who was diagnosed 
with aspergillosis of the retro-orbital area and paranasal 
sinuses, had suffered from SLE and received long-term steroid 
and immunosuppressive medication, rendering her vulnerable 
to opportunistic infections.
Aspergillus sp. is very common in the environment. This 
group of fungi has hyaline (nonpigmented), septate, and 
branching hyphae that give rise to numerous conidia (spores). 
Aspergillus fumigatus is the most common cause of invasive 
aspergillosis.5 The main risk factors are severe neutropenia 
and the use of corticosteroids, although this disease can 
also occur in individuals without those conditions. The risk 
of invasive aspergillosis and mortality associated with this 
disease are also increased with longer duration and higher 
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The initial presentation of our patient was a condition 
called orbital apex syndrome, a group of rarely encountered 
symptoms consisting of ophthalmoplegia, ptosis, and vision 
loss. Several conditions that can cause orbital apex syndrome 
are malignancy, infl ammation, or, as in our case, infection. 
Because of its poor prognosis, diagnosis must be made early, 
especially when there is evidence of immunodefi ciency risk 
factors.9–11 Unfortunately, due to the posteriorly located mass 
at the orbital apex, the diagnosis of our patient was made 4 
months after the development of initial symptoms.
Sinus involvement occurs in 5–10% cases of invasive 
aspergillosis. Other than fever, common symptoms are 
uncomfortable sensation in the nose or face, nasal congestion, 
and rhinorrhea, which sometimes are accompanied with blood. 
Asymmetric and swollen face, epistaxis, proptosis, cranial 
nerve abnormalities, and bone erosion are suggestive of 
fungal infection. Computed tomography or MRI are important 
diagnostic procedures but they lack the ability to distinguish 
between sinusitis caused by invasive aspergillosis and other 
forms of sinusitis, such as allergic, bacterial, or other fungal 
sinusitis.5,9
Defi nitive diagnosis is made when one of the following 
is found: (1) positive culture of samples obtained from the 
affected lesion (e.g. brain abscess); or (2) positive histological 
examination and culture from samples obtained from the 
affected organ (e.g. sinus or skin). In our case, the patient had 
positive culture and showed histological feature of invasive 
aspergillosis.
Diagnosis of invasive aspergillosis can also be made by 
detection of galactomannan antigen or β-D-glucan; both are 
components of fungal cell wall. Galactomannan antigen is 
more specifi c in diagnosing invasive aspergillosis, while β-D-
glucan may be detected in other invasive fungal infections. A 
meta-analysis showed that serum galactomannan antigen test 
has sensitivity and specifi city of 71% and 89%, respectively. 
Histopathological examination may reveal area of infarction, 
invasion of hyphae into the blood vessels, or acute necrosis 
with limited infl ammation. Aspergillus hyphae could be 
characterized as hyaline, narrow, septate, and dichotomously 
branching hyphae.9
Culture is important in confi rming the diagnosis of 
aspergillosis, since there are only very few other species of 
fungi that have similar histological features. Fungal growth 
medium is more sensitive than bacterial medium. From all 
cases of invasive aspergillosis, only 10–30% show positive 
culture, and about 40% are only diagnosed at autopsy.5,9
Several antifungals have been known to be effective 
in treating invasive aspergillosis, such as voriconazole, 
itraconazole, posaconazole, caspofungin, micafungin, and 
amphotericin B. Voriconazole is the fi rst line agent, while 
caspofungin, posaconazole, and amphotericin B lipid complex 
are second line agents. Intravenous administration is usually 
preferred in invasive aspergillosis. Duration of treatment 
varies from 3 months to several years, depending on host 
immunity and treatment response. Recurrence of infection 
may happen if there is suboptimal response to treatment or 
defective immune system.
Due to several limitations, our patient did not receive 
voriconazole as her treatment. It was then decided to 
give her amphotericin B as an alternative, administered 
both intravenously and locally (as intraconal irrigation). 
Amphotericin B exhibit fungicidal activity. Its potency 
depends on serum concentration and pathogen susceptibility. 
Amphotericin B may be administered intravenously, topically, 
or, in cases of ophthalmic infection, intravitreally and 
intracamerally.12–14 Reported adverse effects of amphotericin 
B include cardiac arrhythmia, acute kidney injury, and 
anemia.15,16
After 14 days, the treatment of our patient was continued 
with oral itraconazole. Itraconazole is the oral agent of choice 
for treating chronic and allergic form of aspergillosis. It is one 
of the azole derivatives, which exert their fungicidal activity 
by inhibiting cell growth, resulting in cell death. Except 
fl uconazole, all of the azole derivatives may lower the immune 
system; thus they may reduce infl ammation, although this 
effect will also decrease their activity. For fungal infection in 
orbital area, the azoles can only act as fungistatic.12 Resistance 
to one or more of the azoles may occur in long-term treatment. 
A prospective study that collected isolate culture from several 
hospitals in the Netherlands had showed that the annual 
prevalence of resistance to itraconazole ranged between 1.7 
and 6%. The study also found that the itraconazole-resistant 
isolates showed elevated minimum inhibitory concentration of 
voriconazole and posaconazole. Besides resistance, it is also 
important to consider potential interaction with other drugs 
before administering voriconazole and itraconazole.17–19
Culture results showed that the Aspergillus infecting 
the patient’s left eye was resistant to itraconazole, and no 
satisfying result was obtained from the treatment with 
itraconazole or amphotericin B; hence readministration of 
voriconazole was decided. A study had showed that as initial 
treatment of invasive aspergillosis, voriconazole was more 
superior in treatment response, survival rates, and safety 
than amphotericin B. The adverse effect commonly found is 
temporary visual disturbance.15
Surgical intervention for invasive aspergillosis can 
sometimes be curative, as in some forms involving bone, heart 
valve, paranasal sinuses, proximal lung, large veins, and in 
cases of brain abscess, keratitis, and endophthalmitis.5 Our 
patient did not undergo surgical treatment since her family did 
not consent to the orbital exenteration.
In situations where there is a medium to high risk of 
fungal infection, antifungal prophylaxis administration for 
superfi cial or systemic candidiasis has been widely accepted. 
Fluconazole and oral itraconazole have no activity against 
Aspergillus sp., and itraconazole solution show only medium 
effi cacy; posaconazole solution may be more effective. Some 
data supports the use of low-dose intravenous micafungin. In 
general, there has not been yet truly effective prophylactive 
regimens.5
In invasive aspergillosis, cure is possible if there is 
improvement of the immune system, while the allergic and 
chronic form is generally incurable. Mortality rate of invasive 
aspergillosis is 50% when properly diagnosed and treated; 
Case Report
Indonesian Journal of Rheumatology 2010; Vol 0240
otherwise it could be as high as 100%. A case report described 
a fatal case of aspergillus sinusitis, in which the infection had 
spread intracerebrally.5,20 One of the factors that improve our 
patient’s chance of survival was that there was no intracerebral 
extension of the infection.
In summary, corticosteroids and immunosuppressants 
treatment in SLE predispose patients to fungal infection, 
including invasive aspergillosis, which is caused by a group 
of fungi called Aspergillus. This disease is known to have poor 
prognosis, high recurrence rates, and there has not been yet 
prophylaxis with proven effi cacy. Diagnosis of aspergillosis 
often presents challenges to the clinicians. There are various 
regimens in treating fungal infection, depending on the 
etiology and severity of infection. Voriconazole has become 
the treatment of choice in severe Aspergillus infection, 
followed by amphotericin B. Resistance to antifungal drugs 
has been reported, resulting in high recurrence rates. In 
invasive aspergillosis, surgical intervention can be considered 
and sometimes is curative.
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